These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17239495)

  • 1. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
    Parra LE; Borja-Cabrera GP; Santos FN; Souza LO; Palatnik-de-Sousa CB; Menz I
    Vaccine; 2007 Mar; 25(12):2180-6. PubMed ID: 17239495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
    Borja-Cabrera GP; Santos FN; Bauer FS; Parra LE; Menz I; Morgado AA; Soares IS; Batista LM; Palatnik-de-Sousa CB
    Vaccine; 2008 Sep; 26(39):4991-7. PubMed ID: 18675868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
    Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
    Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
    Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
    Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.
    Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM
    Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.
    Palatnik-de-Sousa CB; Silva-Antunes I; Morgado Ade A; Menz I; Palatnik M; Lavor C
    Vaccine; 2009 Jun; 27(27):3505-12. PubMed ID: 19464528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.
    Santos FN; Borja-Cabrera GP; Miyashiro LM; Grechi J; Reis AB; Moreira MA; Martins Filho OA; Luvizotto MC; Menz I; Pessôa LM; Gonçalves PR; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2007 Aug; 25(33):6176-90. PubMed ID: 17630055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
    Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for visceral leishmaniasis: A review.
    Jain K; Jain NK
    J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine.
    Dantas-Torres F
    Vet Parasitol; 2006 Oct; 141(1-2):1-8. PubMed ID: 16750885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
    Palatnik-de-Sousa CB
    Front Immunol; 2019; 10():813. PubMed ID: 31040850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis.
    Borja-Cabrera GP; Santos FN; Santos FB; Trivellato FA; Kawasaki JK; Costa AC; Castro T; Nogueira FS; Moreira MA; Luvizotto MC; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2010 Jan; 28(3):597-603. PubMed ID: 19800443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).
    da Silva VO; Borja-Cabrera GP; Correia Pontes NN; de Souza EP; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2000 Dec; 19(9-10):1082-92. PubMed ID: 11137242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.